Hormone · Profile

Tamoxifen

Nolvadex · TAM · SERM

Hormone ManagementApproved

MW: 371.5g/mol
Formula: C26H29NO

Tamoxifen (TAM) is a selective estrogen receptor modulator primarily used in the management of estrogen receptor-positive breast cancer. Researchers primarily study TAM for its effects on cancer cell growth and its mechanisms of resistance, as well as its potential side effects, including retinal toxicity and hepatotoxicity. Key findings indicate that TAM can lead to retinal damage in a small percentage of patients and that its effectiveness may be compromised by resistance mechanisms involving factors like reactive oxygen species and gut microbiota interactions. Current research continues to explore the complex biological activities of TAM, aiming to understand its side effects and improve therapeutic strategies for breast cancer management. Clinical evidence indicates that addressing TAM resistance and its associated toxicities remains a significant focus in ongoing studies.

Overview

Übersicht

Tamoxifen, also known as Nolvadex, TAM, or SERM (Selective Estrogen Receptor Modulator), is a synthetic compound used primarily in the management of hormone-related conditions, particularly breast cancer. It belongs to the class of selective estrogen receptor modulators and is not naturally produced in the body. Tamoxifen is synthesized for therapeutic purposes and is widely used in clinical settings. Researchers have extensively studied its effects on estrogen receptors, which are present in various tissues, including breast tissue and the retina. The primary physiological role of tamoxifen is to act as an antagonist to estrogen receptors in breast tissue, thereby inhibiting the growth of estrogen-dependent tumors. It is primarily used in the treatment and prevention of estrogen receptor-positive breast cancer. Additionally, tamoxifen has been researched for its effects on other tissues, such as the retina, where it can cause retinopathy, and the liver, where it may induce hepatotoxicity. Tamoxifen's mechanism of action involves binding to estrogen receptors, thereby blocking the proliferative action of estrogen in breast tissue. This blockade can lead to the inhibition of tumor growth in estrogen receptor-positive breast cancer. However, resistance to tamoxifen is a significant clinical challenge, with mechanisms involving pathways such as RelB and GPX4 contributing to this resistance. Pharmacokinetically, tamoxifen is well-absorbed orally, with a bioavailability that is not significantly affected by first-pass metabolism. It has a long half-life, allowing for once-daily dosing. Tamoxifen is metabolized in the liver, primarily by cytochrome P450 enzymes, into active metabolites that contribute to its therapeutic effects. Clinically, tamoxifen is approved for use in the treatment of breast cancer and is a standard part of endocrine therapy for estrogen receptor-positive cases. It is regulated by health authorities worldwide, with specific legal statuses in different countries.

Chemical profile

Chemische Struktur

Formel	C26H29NO
Molekulargewicht	371.5g/mol
CAS-Nummer	10540-29-1
PubChem CID	2733526

Mechanism

Wirkmechanismus

Tamoxifen acts primarily on estrogen receptors, blocking the estrogen-mediated signaling pathways that promote cell proliferation in breast tissue. This action inhibits the growth of estrogen receptor-positive tumors and can lead to tumor regression.

Mechanism

Signalweg

Tamoxifen (TAM) acts primarily as a selective estrogen receptor modulator (SERM) by competitively inhibiting estrogen receptors (ERα) in breast cancer cells, thereby blocking estrogen-mediated signaling pathways critical for tumor growth. Additionally, TAM influences mitochondrial function and reactive oxygen species (ROS) levels, which can induce ferroptosis, a regulated form of cell death, particularly in TAM-sensitive cells, while resistance mechanisms may involve upregulation of glutathione peroxidase 4 (GPX4) via RelB signaling. The precise molecular mechanisms underlying TAM-induced hepatotoxicity and its effects on gut microbiota and bile acid metabolism remain incompletely understood.

Half-Life & Pharmacokinetics

POOral

Half-life is approximately 5 to 7 days due to active metabolites.

Tamoxifen is metabolized into active metabolites, such as endoxifen, which contribute to its long half-life and therapeutic effects.

Storage

Temperature

Store at room temperature (15-30C)

Light

Protect from light

Form

Stable in tablet form for extended periods

Notes

Ensure storage in a dry place to maintain stability.

Solubility

Löslichkeit

Tamoxifen is poorly soluble in water but more soluble in organic solvents such as ethanol.

Legal Status

🇩🇪DE

Verschreibungspflichtig (prescription only); not a controlled substance under BtMG.

🇺🇸US

FDA approved for breast cancer treatment; prescription only.

🇦🇺AU

TGA Schedule 4 (prescription only medicine).

🇬🇧UK

Prescription only medicine (POM) under MHRA guidelines.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Open Questions

Offene Forschungsfragen

Current evidence is limited regarding the long-term effects and mechanisms of tamoxifen-induced retinopathy, particularly the optimal screening methods for early detection and the variability in incidence rates among different populations. Further research is needed to elucidate the multifactorial mechanisms underlying tamoxifen resistance in breast cancer, including the role of emerging molecular targets and the influence of tumor heterogeneity. Additionally, the relationship between tamoxifen-induced hepatotoxicity and gut microbiota dysbiosis requires further investigation, particularly through larger randomized controlled trials and studies focusing on specific patient populations to better understand the implications for clinical management.

189 Research Publications

3,770

Total Citations

Human/RCT

2.0

Avg. Influence

2026

Latest

Sort

Filter

01Top

#01

Tamoxifen ("Nolvadex"): a review.

Clemons M, et al. · Cancer treatment reviews · 2002

ReviewInfluence6.0

222

The review highlighted that tamoxifen remains the hormonal treatment of choice for estrogen-receptor positive breast cancer due to its efficacy and tolerability, despite ongoing studies to optimize its use.

Key findings

01Tamoxifen is effective for both early and advanced breast cancer.
02It works well for both pre- and postmenopausal women.
03Ongoing studies are exploring the best duration of treatment and comparisons with newer therapies.

PubMed

02Top

#02

Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.

In VitroInfluence8.0

214

The study demonstrated that tumor-associated macrophages secrete CCL2, which activates the PI3K/Akt/mTOR pathway and promotes tamoxifen resistance in breast cancer.

PubMed

03Top

#03

Tamoxifen resistance in breast cancer.

ReviewInfluence9.0

165

The study demonstrated that tamoxifen resistance in breast cancer may be multifactorial, with altered growth factor production and pharmacologic mechanisms contributing to treatment failure.

PubMed

#04

Tamoxifen Resistance: Emerging Molecular Targets.

ReviewInfluence4.0

125

The review highlighted that tamoxifen resistance in breast cancer is multifactorial and may involve novel molecular targets, emphasizing the need for further molecular analysis to optimize therapeutic strategies.

PubMed

#05

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

In VitroInfluence7.0

101

The study demonstrated that the UGT1A4 codon 48 Leu>Val polymorphism significantly alters glucuronidation rates of tamoxifen and its metabolites, potentially impacting individual responses to tamoxifen therapy.

PubMed

#06

Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase.

In Vitro

Researchers observed that hydroxycitric acid enhances the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells by inhibiting ATP citrate lyase.

PubMed

#07

Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.

AnimalInfluence1.0

Researchers observed distinct gene expression patterns between tamoxifen-sensitive and tamoxifen-resistant human breast cancer xenografts, identifying potential biomarkers for resistance.

PubMed

#08

A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines.

In VitroInfluence1.0

Researchers observed that the ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action, producing cytotoxic effects in both ER-positive and ER-negative breast cancer cell lines.

PubMed

#09

RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer.

Xu Zhi, et al. · Redox biology · 2023

HumanInfluence1.0

The study demonstrated that RelB upregulation inhibits ferroptosis and contributes to tamoxifen resistance in breast cancer by increasing glutathione peroxidase 4 levels, suggesting a potential therapeutic target for overcoming resistance.

Key findings

01RelB contributes to tamoxifen resistance in breast cancer by inhibiting ferroptosis.
02Higher levels of RelB and GPX4 in sensitive cells increase resistance to tamoxifen.
03Decreasing RelB and GPX4 in resistant cells enhances their sensitivity to tamoxifen.

PubMed

#10

Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles.

ReviewInfluence3.0

Researchers observed that novel tamoxifen nanoformulations can selectively deliver lower doses of tamoxifen to breast tumors, potentially reducing toxicity while maintaining efficacy.

PubMed

Clinical Trials (145)

Preclinical

Phase I

Phase II

Phase III

Approved

145

Total Trials

96,013

Total Enrolled

Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms

NCT06982313COMPLETED

Sponsor

Ente Ospedaliero Ospedali Galliera

Enrollment

1,545

Started

1996

Primary outcome

Incidence of invasive breast cancer and breast cancer-free interval

Breast Cancer Invasive

CYP2D6 Genotype on the Clinical Effect of Tamoxifen

NCT00973037UNKNOWN

Sponsor

Korea University Anam Hospital

Enrollment

922

Started

2009

Primary outcome

Disease-free survival(DFS)

Breast NeoplasmsTamoxifenGenotypeCYP2D6

Neoadjuvant Treatment of Breast Cancer

NCT05131893NOT_YET_RECRUITING

Sponsor

National Institute of Oncology, Hungary

Enrollment

300

Started

2022

Primary outcome

pathological complete remission rate

Breast Cancer

Breast Cancer & Antiestrogenic Therapy & Brain

NCT06346457UNKNOWN

Sponsor

International Research Training Group 2804

Enrollment

180

Started

2024

Primary outcome

Correlations between antiestrogen hormone therapy and brain function & structure

Breast Cancer FemaleHealthy FemaleMenopauseAnti-estrogenic Therapy

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

NCT04312347COMPLETED

Sponsor

Nalagenetics Pte Ltd

Enrollment

151

Started

2019

Primary outcome

Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolites

ER+ Breast Cancer

Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms

NCT01075802COMPLETED

Sponsor

Western Sydney Local Health District

Enrollment

121

Started

2010

Primary outcome

Effects of genotype of CYP2D on plasma and serum concentration of tamoxifen and its metabolites, with consequent recommendation for dosage adjustment

Breast CancerCYP2D6 Polymorphism

Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen

NCT03582865UNKNOWN

Sponsor

Assiut University

Enrollment

100

Started

2019

Primary outcome

Estimate the frequency of Cyp2D6*1 and *4 alleles in Egyptian patients maintained on tamoxifen (20 mg/day) for management of ER +ve breast cancer.

Breast Cancer

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

NCT00126464UNKNOWN

Sponsor

Cedars-Sinai Medical Center

Enrollment

100

Started

2004

Primary outcome

Molecular markers of the estrogen pathway as measured by immunohistochemistry at 3 weeks

Breast Cancer

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121COMPLETED

Sponsor

Mayo Clinic

Enrollment

Started

2011

Primary outcome

Percent change in plasma concentrations of 4-hydroxy tamoxifen and of endoxifen after ≥ 8 weeks of concurrent administration of tamoxifen citrate and a CYP2D6 inhibitor

Breast CancerDepressionHot FlashesPsychosocial Effects of Cancer and Its Treatment

Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen

NCT07145827COMPLETED

Sponsor

Uruk University

Enrollment

Started

2024

Primary outcome

Change in endometrial thickness

Breast CancerEndometrial Hyperplasia and Endometrial Cancers

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032COMPLETED

Sponsor

Virginia Commonwealth University

Enrollment

Started

2011

Primary outcome

The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment

Ductal Breast Carcinoma in SituLobular Breast Carcinoma in SituStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

NCT01027416COMPLETED

Sponsor

Roswell Park Cancer Institute

Enrollment

Started

2009

Primary outcome

Mean Percent Positive Proximity Ligation Assays of All Tumor Protein p53-wild Type Breast Tumors in Participants by Treatment Arm

Breast Cancer

Impact of Low-dose Tamoxifen on BPU

NCT02979301COMPLETED

Sponsor

Mayo Clinic

Enrollment

Started

2017

Primary outcome

Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)

High Background Uptake on MBI

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

NCT01169792COMPLETED

Sponsor

Yonsei University

Primary outcome

The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients

Breast NeoplasmsSurvival AnalysisAntineoplastic AgentsTherapeutic Uses

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195Phase 4ACTIVE_NOT_RECRUITING

Sponsor

Novartis Pharmaceuticals

Enrollment

134

Started

2022

Primary outcome

Percentage of participants with treatment-emergent adverse events (AES)

Metastatic Breast Cancer

The Effect of Tamoxifen on Clinical Outcome in Women With Thin Endometrium Undergoing Frozen Thawed Cycle.

NCT03060304Phase 4UNKNOWN

Sponsor

Sun Yat-sen University

Enrollment

100

Started

2017

Primary outcome

endometrium thickness

Endometrium

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224Phase 4COMPLETED

Sponsor

Oregon Health and Science University

Enrollment

Started

2016

Primary outcome

Number of Bleeding and Spotting Days

MenorrhagiaMetrorrhagiaMedicated Intrauterine Devices

Tamoxifen in Treating Women With Breast Cancer

NCT00003678Phase 3UNKNOWN

Sponsor

University Hospital Birmingham

Enrollment

20,000

Started

1991

Primary outcome

All-cause mortality

Breast Cancer

Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer

NCT00003016Phase 3UNKNOWN

Sponsor

University of Oxford

Enrollment

20,000

Started

1995

Primary outcome

Overall survival (i.e., all-cause mortality)

Breast Cancer

Tamoxifen for the Prevention of Breast Cancer in High-Risk Women

NCT00002644Phase 3COMPLETED

Sponsor

Queen Mary University of London

Enrollment

7,154

Started

1994

Breast Cancer

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

NCT00002582Phase 3COMPLETED

Sponsor

Institute of Cancer Research, United Kingdom

Enrollment

6,000

Started

1993

Breast Cancer

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970Phase 3COMPLETED

Sponsor

National Cancer Institute (NCI)

Enrollment

3,436

Started

2000

Primary outcome

Duration of DFS

Breast AdenocarcinomaHER2 Positive Breast CarcinomaStage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

NCT00002707Phase 3COMPLETED

Sponsor

NSABP Foundation Inc

Enrollment

2,411

Started

1995

Primary outcome

Determine if 4 cycle of pre-op or post-op Taxotere given after 4 cycles of pre-op AC will more effectively prolong survival (S) than does 4 cycles of pre-op AC alone.

Breast Cancer

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

NCT00002579Phase 3COMPLETED

Sponsor

Scottish Cancer Therapy Network

Enrollment

2,000

Started

1993

Breast Cancer

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

NCT05780567Phase 3ACTIVE_NOT_RECRUITING

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

1,946

Started

2023

Primary outcome

Invasive Disease-Free Survival (IDFS)

Breast Cancer

Cognition in the Study of Tamoxifen and Raloxifene

NCT00687102Phase 3COMPLETED

Sponsor

Wake Forest University

Enrollment

1,498

Started

2001

Primary outcome

Mean Change From Baseline on the the Benton Visual Retention Test Scores by Treatment Group

CognitionAging

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

NCT00002581Phase 3COMPLETED

Sponsor

Scottish Cancer Therapy Network

Enrollment

1,000

Started

1993

Breast Cancer

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

NCT00793377Phase 3COMPLETED

Sponsor

GBG Forschungs GmbH

Enrollment

913

Primary outcome

Pathological locoregional complete tumor response (pCR) between both arms

Primary Breast Cancer

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00097344Phase 3TERMINATED

Sponsor

Intarcia Therapeutics

Enrollment

842

Started

2004

Primary outcome

Time to progression

Breast NeoplasmsNeoplasms, Hormone-Dependent

Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

NCT04046159Phase 3UNKNOWN

Sponsor

National Taiwan University Hospital

Enrollment

810

Started

2019

Primary outcome

Breast tumor recurrence

Breast Ductal Carcinoma in Situ

Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

NCT00201851Phase 3COMPLETED

Sponsor

International Breast Cancer Research Foundation

Enrollment

740

Started

2004

Primary outcome

Disease-free Survival

Breast Cancer

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

NCT02062489Phase 3UNKNOWN

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

688

Started

2014

Primary outcome

Disease-free survival of patients

Breast Cancer

The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)

NCT00152178Phase 3COMPLETED

Sponsor

Taiho Pharmaceutical Co., Ltd.

Enrollment

680

Started

1996

Primary outcome

Relapse-free survival

Breast Cancer

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

NCT02914158Phase 3UNKNOWN

Sponsor

First Affiliated Hospital, Sun Yat-Sen University

Enrollment

680

Started

2016

Primary outcome

Disease-Free Survival (DFS)

Breast Cancer

Tamoxifen in Treating Women With High-Risk Breast Cancer

NCT00002542Phase 3COMPLETED

Sponsor

NCIC Clinical Trials Group

Enrollment

672

Started

1993

Breast Cancer

Adjuvant AI Combined With Zoladex

NCT01352091Phase 3UNKNOWN

Sponsor

Fudan University

Enrollment

670

Started

2008

Primary outcome

DFS

Breast Cancer

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

NCT00002720Phase 3COMPLETED

Sponsor

European Institute of Oncology

Enrollment

642

Started

1995

Breast Cancer

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery

NCT07762885Phase 3RECRUITING

Sponsor

Fudan University

Enrollment

636

Started

2026

Primary outcome

Ipsilateral Breast Tumor Recurrence (IBTR)

Ductal Carcinoma In Situ, DCIS

Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

NCT00003857Phase 3COMPLETED

Sponsor

Radiation Therapy Oncology Group

Enrollment

636

Started

1999

Primary outcome

Local recurrence (e.g., invasive or noninvasive recurrence)

Breast Cancer

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00002755Phase 3COMPLETED

Sponsor

Scottish Cancer Therapy Network

Enrollment

600

Started

1995

Breast Cancer

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer

NCT00002528Phase 3COMPLETED

Sponsor

ETOP IBCSG Partners Foundation

Enrollment

473

Started

1993

Primary outcome

Disease-free survival

Breast Cancer

External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe Mastalgia

NCT06404775Phase 3NOT_YET_RECRUITING

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

456

Started

2025

Primary outcome

Mastalgia clinical response rate

Mastalgia

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

NCT00003013Phase 3COMPLETED

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Enrollment

450

Started

1996

Breast Cancer

Combination Chemotherapy in Treating Women With Breast Cancer

NCT00047099Phase 3COMPLETED

Sponsor

Ludwig-Maximilians - University of Munich

Enrollment

446

Started

2001

Primary outcome

Comparison of time to progression

Breast Cancer

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276Phase 3TERMINATED

Sponsor

National Cancer Institute (NCI)

Enrollment

396

Started

2001

Primary outcome

Median number of positive axillary lymph nodes

Cardiac ToxicityInflammatory Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Breast Cancer

Combination Chemotherapy in Treating Women With Breast Cancer

NCT00003679Phase 3UNKNOWN

Sponsor

Scottish Cancer Therapy Network

Enrollment

350

Started

1998

Breast Cancer

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

NCT00002784Phase 3COMPLETED

Sponsor

ETOP IBCSG Partners Foundation

Enrollment

344

Started

1996

Primary outcome

Disease-free survival.

Breast Cancer

ATAC - Bone Density Sub-Protocol

NCT00784940Phase 3COMPLETED

Sponsor

AstraZeneca

Enrollment

308

Started

1998

Primary outcome

Time to withdrawal

Bone Density

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

NCT00003680Phase 3UNKNOWN

Sponsor

Scottish Cancer Therapy Network

Enrollment

300

Started

1998

Breast Cancer

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

NCT00003972Phase 3COMPLETED

Sponsor

Fred Hutchinson Cancer Center

Enrollment

280

Started

1998

Breast Cancer

Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients

NCT00896155Phase 3UNKNOWN

Sponsor

Tata Memorial Hospital

Enrollment

260

Started

2008

Primary outcome

Development of Lung fibrosis

Pulmonary FibrosisBreast Cancer

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

NCT04906395Phase 3ACTIVE_NOT_RECRUITING

Sponsor

Tolmar Inc.

Enrollment

250

Started

2021

Primary outcome

Suppression of ovarian function

Breast Cancer

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

NCT00293540Phase 3COMPLETED

Sponsor

International Breast Cancer Research Foundation

Enrollment

249

Started

2006

Primary outcome

Overall Survival

Breast Cancer

Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

NCT02728622Phase 3COMPLETED

Sponsor

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Enrollment

241

Started

2002

Primary outcome

Quality-adjusted survival

Ovarian CancerPeritoneal CancerCancer of the Fallopian Tube

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00003032Phase 3COMPLETED

Sponsor

NCIC Clinical Trials Group

Enrollment

224

Started

1997

Breast Cancer

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

NCT00267553Phase 3TERMINATED

Sponsor

Intarcia Therapeutics

Enrollment

200

Started

2005

Primary outcome

In conjunction with the data from Biomed 777-CLP-29, compare the time to progression (TTP) in the atamestane plus toremifene arm to the TTP in the letrozole plus placebo arm

Breast NeoplasmsNeoplasms, Hormone-Dependent

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

NCT00605267Phase 3COMPLETED

Sponsor

AstraZeneca

Enrollment

197

Started

2007

Primary outcome

Best Overall Response Rate (BORR) (Calliper)

Breast Cancer

Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

NCT00233610Phase 3COMPLETED

Sponsor

AstraZeneca

Enrollment

180

Started

2003

Primary outcome

Incidence of Gynecomastia and Breast pain at 2, 6 months and every 6 months thereafter and/or at withdrawal visit.

Prostate Cancer

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

NCT05016349Phase 3UNKNOWN

Sponsor

Mahmoud Ramadan mohamed Elkazzaz

Enrollment

160

Started

2021

Primary outcome

Cytokeratin 5 (CK5)-expression

Breast Cancer Female

Tamoxifen Citrate in Patients With Breast Cancer

NCT00963209Phase 3UNKNOWN

Sponsor

Centre Hospitalier Universitaire Vaudois

Enrollment

140

Started

2009

Primary outcome

Determination of CYP2D6 genotype and determination of plasma concentrations of tamoxifen citrate and its metabolites (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen) under the 20 mg daily and 40 mg daily schedules

Breast Cancer

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00041080Phase 3COMPLETED

Sponsor

National Cancer Institute (NCI)

Enrollment

139

Started

2003

Primary outcome

Median Progression-free Survival

Fallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer

Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy

NCT02382094Phase 3COMPLETED

Sponsor

Karolinska University Hospital

Enrollment

110

Started

2005

Primary outcome

Quality of Life

Prostate Cancer

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

NCT01638247Phase 3COMPLETED

Sponsor

GBG Forschungs GmbH

Enrollment

Started

2012

Primary outcome

Estradiol blood concentation

Male Breast Cancer

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

NCT00034125Phase 3COMPLETED

Sponsor

Eli Lilly and Company

Breast Neoplasms

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967Phase 3COMPLETED

Sponsor

NSABP Foundation Inc

Started

1997

Breast Cancer

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

NCT00004125Phase 3COMPLETED

Sponsor

Eastern Cooperative Oncology Group

Started

1999

Breast Cancer

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00010322Phase 3TERMINATED

Sponsor

Intarcia Therapeutics

Started

2000

Breast Cancer

Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer

NCT00006030Phase 3UNKNOWN

Sponsor

British Association of Surgical Oncology: Breast Group

Started

1992

Breast Cancer

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

NCT02132000Phase 2/3UNKNOWN

Sponsor

Fengxi Su

Enrollment

3,036

Started

2014

Primary outcome

survival outcomes: disease free survival

Breast Cancer Patients in PremenopausalEstrogen and/or Progesterone Receptor Positive

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788Phase 2/3COMPLETED

Sponsor

National Cancer Institute (NCI)

Enrollment

260

Started

2014

Primary outcome

Progression-free Survival (PFS)

Borderline Ovarian Serous TumorMicropapillary Serous CarcinomaOvarian Serous AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaRecurrent Ovarian Low Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Serous Adenocarcinoma

Maintenance Hormonal Therapy and DLBCL

NCT06355401Phase 2/3NOT_YET_RECRUITING

Sponsor

Sohag University

Enrollment

100

Started

2024

Primary outcome

disease free survival

Diffuse Large B Cell Lymphoma

Low Dose Tamoxifen for Mammographic Density Reduction

NCT03346200Phase 2COMPLETED

Sponsor

Per Hall

Enrollment

1,440

Started

2016

Primary outcome

Mammograpic Density Change

Risk ReductionMammographic Density Reduction

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

NCT01771458Phase 2COMPLETED

Sponsor

Institut Curie

Enrollment

742

Started

2012

Primary outcome

Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy.

Reccurent/Metastatic Solid Tumor Disease

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322Phase 2COMPLETED

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment

501

Started

2008

Primary outcome

Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes

Breast CancerMenopausal Symptoms

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

NCT03161353Phase 2ACTIVE_NOT_RECRUITING

Sponsor

MedSIR

Enrollment

377

Started

2017

Primary outcome

Evaluate the rate of pCR

Breast Cancer

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

NCT00229697Phase 2COMPLETED

Sponsor

AstraZeneca

Enrollment

317

Started

2003

Primary outcome

Strata 1: To compare the time to progression between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex)

Breast Neoplasms

Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer

NCT00738777Phase 2SUSPENDED

Sponsor

The Netherlands Cancer Institute

Enrollment

250

Started

2008

Primary outcome

Decrease in tumor cell proliferation and induced apoptosis.

Breast Cancer

SHORTened Duration of TAMoxifen

NCT07806630Phase 2ACTIVE_NOT_RECRUITING

Sponsor

Rutgers, The State University of New Jersey

Enrollment

250

Started

2026

Primary outcome

Low Dose Tamoxifen

High Risk for Invasive Breast Cancer

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

NCT02747004Phase 2ACTIVE_NOT_RECRUITING

Sponsor

Eli Lilly and Company

Enrollment

234

Started

2016

Primary outcome

Progression Free Survival (PFS)

Metastatic Breast Cancer

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

NCT00305838Phase 2UNKNOWN

Sponsor

Mount Vernon Cancer Centre at Mount Vernon Hospital

Enrollment

200

Started

2004

Primary outcome

Percentage of patients who have a log linear rise in CA 125 levels

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus

NCT04389580Phase 2UNKNOWN

Sponsor

Kafrelsheikh University

Enrollment

160

Started

2021

Primary outcome

lung injury score

COVID-19

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

NCT07729046Phase 2NOT_YET_RECRUITING

Sponsor

University of California, San Diego

Enrollment

150

Started

2027

Primary outcome

Median Progression-Free Survival

Metastatic Invasive Breast CancerResistant Breast CancerER+, HER2-, Metastatic Breast Cancer

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

NCT06364267Phase 2RECRUITING

Sponsor

Andrea DeCensi

Enrollment

140

Started

2025

Primary outcome

Quality of life MEnQol

Breast Cancer

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369Phase 2TERMINATED

Sponsor

University of Texas Southwestern Medical Center

Enrollment

130

Started

2000

Primary outcome

Plasma levels of hormones and binding proteins as measured by ELISA, IHC, and TUNEL at baseline and 3 months

Breast Cancer

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695Phase 2COMPLETED

Sponsor

ECOG-ACRIN Cancer Research Group

Enrollment

124

Started

2011

Primary outcome

Progression-free Survival by CYP2D6 Status in 2 Categories

Breast CancerStage IV Breast Cancer

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720Phase 2COMPLETED

Sponsor

Alliance for Clinical Trials in Oncology

Enrollment

112

Started

2002

Primary outcome

Change in number of daily hot flushes at 3 months from baseline

Breast CancerHot FlashesHot Flushes

Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility

NCT05200663Phase 2UNKNOWN

Sponsor

Sharif Medical Research Center

Enrollment

110

Started

2021

Primary outcome

Semen Volume

OligoasthenoteratozoospermiaMale Infertility

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer

NCT02890082Phase 2ACTIVE_NOT_RECRUITING

Sponsor

Institut Cancerologie de l'Ouest

Enrollment

102

Started

2014

Primary outcome

Assess the feasibility of ovarian stimulation combining tamoxifen with recombinant FSH (follicle stimulating hormone ) followed by oocyte vitrification and / or embryo freezing before chemotherapy for breast cancer.

Breast Cancer

Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]

NCT00214110Phase 2COMPLETED

Sponsor

University of Wisconsin, Madison

Enrollment

100

Started

2001

Primary outcome

Stability at 6, 12, 18 and 24 months on of the patient's mean percent predicted arm strength

Amyotrophic Lateral Sclerosis (ALS)

Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.

NCT02866955Phase 2COMPLETED

Sponsor

Institut de Cancérologie de Lorraine

Enrollment

100

Started

2011

Primary outcome

Progression-free survival after a 6- month monotherapy with Estramustine in patients with HER2-/RH+ breast cancer progressing

Breast Cancer

Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients

NCT07535905Phase 2NOT_YET_RECRUITING

Sponsor

University Health Network, Toronto

Enrollment

Started

2026

Primary outcome

Normal Testosterone Recovery

HypogonadismProstate Cancer

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

NCT05982093Phase 2RECRUITING

Sponsor

SOLTI Breast Cancer Research Group

Enrollment

Started

2023

Primary outcome

To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC

Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorPremenopausal Breast Cancer

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

NCT00398489Phase 2UNKNOWN

Sponsor

Technical University of Munich

Enrollment

Started

2006

Primary outcome

Rate of pathologic complete remission (pCR) after neoadjuvant therapy comprising docetaxel and trastuzumab (Herceptin®) in women with locally advanced, HER2-positive, operable breast cancer

Breast Cancer

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936Phase 2ACTIVE_NOT_RECRUITING

Sponsor

University of Alabama at Birmingham

Enrollment

Started

2010

Primary outcome

Mammographic Breast Density

Breast Cancer

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

NCT04272801Phase 2ACTIVE_NOT_RECRUITING

Sponsor

Shayna Showalter, MD

Enrollment

Started

2020

Primary outcome

Number of Participants Who Changed Their Preference for Adjuvant Radiation Treatment

Breast Cancer Female

The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers

NCT03211572Phase 2UNKNOWN

Sponsor

Ottawa Hospital Research Institute

Enrollment

Started

2017

Primary outcome

Endocrine Therapy response

Breast Cancer

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

NCT00492687Phase 2UNKNOWN

Sponsor

San Diego Pacific Oncology & Hematology Associates

Enrollment

Started

2006

Primary outcome

Progression-free survival

Brain and Central Nervous System Tumors

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

NCT00068419Phase 2COMPLETED

Sponsor

Children's Oncology Group

Enrollment

Started

2004

Primary outcome

Percentage of Patients Failure Free at 2 Years Following Study Entry

Desmoid Tumor

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306Phase 2RECRUITING

Sponsor

National Cancer Institute (NCI)

Enrollment

Started

2025

Primary outcome

Change in serum adiponectin

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956Phase 2TERMINATED

Sponsor

Mayo Clinic

Enrollment

Started

2021

Primary outcome

Change in Median Lobular Ki67 From Pre-Tamoxifen Breast Biopsy to On-Tamoxifen Biopsy With 4 Weeks of Intervention

Breast Atypical HyperplasiaBreast Lobular Carcinoma in SituBreast Atypical Lobular HyperplasiaBreast Carcinoma

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581Phase 2COMPLETED

Sponsor

Nazem Atassi

Enrollment

Started

2011

Primary outcome

Change in ALS Functional Rating Scale - Revised (ALSFRS-R)

Amyotrophic Lateral Sclerosis

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

NCT02970682Phase 2COMPLETED

Sponsor

Evgen Pharma

Enrollment

Started

2016

Primary outcome

Treatment-Emergent Adverse Events [Safety and Tolerability])

Breast Neoplasm

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

NCT04765098Phase 2RECRUITING

Sponsor

AHS Cancer Control Alberta

Enrollment

Started

2022

Primary outcome

3 month progression-free survival

Glioblastoma Multiforme

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

NCT00003099Phase 2COMPLETED

Sponsor

M.D. Anderson Cancer Center

Enrollment

Started

1996

Primary outcome

Fenretinide + Tamoxifen effectiveness given before surgery in treating breast cancer

Breast Cancer

Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?

NCT00206544Phase 2COMPLETED

Sponsor

The Alfred

Enrollment

Started

2004

Primary outcome

Scores on CARS-M Scale at trial completion

Bipolar DisorderManiaSchizoaffective Disorder

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

NCT00489944Phase 2UNKNOWN

Sponsor

San Diego Pacific Oncology & Hematology Associates

Enrollment

Started

2007

Primary outcome

Disease-free survival

Intraocular Melanoma

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199Phase 2COMPLETED

Sponsor

Fred Hutchinson Cancer Center

Enrollment

Started

1997

Primary outcome

Event-free Survival

Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerInflammatory Breast CancerMale Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast CancerStage IIIB Breast CancerStage IV Breast Cancer

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

NCT00194779Phase 2COMPLETED

Sponsor

University of Washington

Enrollment

Started

2003

Primary outcome

Combined Rate of Microscopic pCR and Macroscopic Pathologic Complete Response (mCR)

Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerHER2-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast Cancer

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

NCT00541138Phase 2COMPLETED

Sponsor

City of Hope Medical Center

Enrollment

Started

2003

Primary outcome

Toxicity profile as assessed by NCI CTC v2.0

Brain and Central Nervous System TumorsMetastatic CancerUnspecified Adult Solid Tumor, Protocol Specific

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer

NCT02404844Phase 2COMPLETED

Sponsor

University Hospital, Essen

Enrollment

Started

2014

Primary outcome

Progression free survival (PFS)-rate in the full population, after 6 months

Breast Cancer

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

NCT05669768Phase 2UNKNOWN

Sponsor

Sun Yat-sen University

Enrollment

Started

2023

Primary outcome

Response rate by CA-125

Ovarian Cancer

Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer

NCT00003050Phase 2COMPLETED

Sponsor

University of Southern California

Enrollment

Started

1997

Breast Cancer

A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix

NCT02482740Phase 2UNKNOWN

Sponsor

Buddhist Tzu Chi General Hospital

Enrollment

Started

2015

Primary outcome

The response rate

Uterine Cervical Neoplasms

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

NCT00003035Phase 2COMPLETED

Sponsor

Georgetown University

Enrollment

Started

1997

Breast Cancer

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

NCT00210028Phase 2TERMINATED

Sponsor

Institut Claudius Regaud

Enrollment

Started

2003

Primary outcome

To evaluate the objective response rate when ZARNESTRA is added to administration of tamoxifen in patients suffering from metastatic or advanced inoperable breast cancer, who are progressing on tamoxifen treatment

Breast Neoplasms

Reversing Therapy Resistance With Epigenetic-Immune Modification

NCT02395627Phase 2TERMINATED

Sponsor

University of California, San Francisco

Enrollment

Started

2015

Primary outcome

Objective Response Rate (ORR)

Breast Neoplasms

Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.

NCT07289035Phase 2NOT_YET_RECRUITING

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Enrollment

Started

2026

Primary outcome

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Cystic Fibrosis - Complete

Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country

NCT02806544Phase 2COMPLETED

Sponsor

Vanderbilt University

Enrollment

Started

2013

Primary outcome

Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility

Breast CancerBreast Neoplasms

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

NCT00002608Phase 2COMPLETED

Sponsor

Ottawa Regional Cancer Centre

Enrollment

Started

1994

Adrenocortical CarcinomaBrain and Central Nervous System TumorsHead and Neck CancerLiver CancerMalignant MesotheliomaPheochromocytomaSarcoma

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

NCT06914674Phase 2RECRUITING

Sponsor

Fudan University

Enrollment

Started

2025

Primary outcome

Progression-free survival (PFSn)

Pancreatic Neoplasms

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

NCT02988986Phase 2COMPLETED

Sponsor

The Methodist Hospital Research Institute

Enrollment

Started

2017

Primary outcome

Ki67 Expression

Estrogen Receptor Positive Breast Cancer

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

NCT03870399Phase 2COMPLETED

Sponsor

AC Camargo Cancer Center

Enrollment

Started

2019

Primary outcome

Disease control rate

Neuroendocrine TumorsProgesterone Receptor Positive TumorEstrogen Receptor Positive Tumor

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

NCT00118157Phase 2COMPLETED

Sponsor

National Cancer Institute (NCI)

Enrollment

Started

2005

Primary outcome

Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)

Estrogen Receptor PositiveMale Breast CarcinomaProgesterone Receptor PositiveRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083Phase 2COMPLETED

Sponsor

University of Nebraska

Enrollment

Started

2006

Primary outcome

Number of Patients With Pathological Complete Response

Breast Cancer

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

NCT02197897Phase 2COMPLETED

Sponsor

Baylor College of Medicine

Enrollment

Started

2015

Primary outcome

Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion

Bladder Cancer

A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

NCT02322853Phase 2TERMINATED

Sponsor

Centre Francois Baclesse

Enrollment

Started

2015

Primary outcome

To define the efficacy (progression-free survival rate at 6 months) of LY2228820 in combination with tamoxifen for postmenopausal women with an ER positive and HER2 negative advanced or metastatic breast cancer who progressed on aromatase inhibitors.

PostmenopausalMetastatic Breast Cancer

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

NCT00206492Phase 2TERMINATED

Sponsor

Baylor Breast Care Center

Enrollment

Started

2003

Primary outcome

cellular response

Breast Cancer

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

NCT00253539Phase 2COMPLETED

Sponsor

The Cleveland Clinic

Enrollment

Started

2002

Primary outcome

Ki67 in breast tissue of enrolled patients

Breast CancerHereditary Breast/Ovarian Cancer (brca1, brca2)

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

NCT01194427Phase 2TERMINATED

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enrollment

Started

2011

Primary outcome

Changes in Markers of Proliferation Prior to and After Study Drug Administration

Stage I Breast CancerStage II Breast CancerStage III Breast CancerInvasive Breast Cancer

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

NCT04190056Phase 2TERMINATED

Sponsor

University of California, San Francisco

Enrollment

Started

2021

Primary outcome

Overall Response Rate (ORR)

Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

NCT00189358Phase 2COMPLETED

Sponsor

AGO Study Group

Primary outcome

Safety and tolerability

Ovarian CancerCancer of the Fallopian TubePeritoneal Cancer

Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma

NCT00024336Phase 2UNKNOWN

Sponsor

Children's Cancer and Leukaemia Group

Started

1999

Brain and Central Nervous System Tumors

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563Phase 1/2COMPLETED

Sponsor

Hoffmann-La Roche

Enrollment

144

Started

2017

Primary outcome

Stage 1: Percentage of Participants With Objective Response

Breast Neoplasms

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA

NCT05378269Phase 1/2COMPLETED

Sponsor

Daré Bioscience, Inc.

Enrollment

Started

2021

Primary outcome

Number of Subjects With Treatment Emergent Adverse Events

Vulvar Atrophy

Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376

NCT04961632Phase 1UNKNOWN

Sponsor

National Cancer Centre, Singapore

Enrollment

Started

2020

Primary outcome

Endoxifen blood concentration

Breast Cancer

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

NCT01821066Phase 1COMPLETED

Sponsor

Pfizer

Enrollment

Started

2013

Primary outcome

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PD-0332991

Healthy

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

NCT00001436Phase 1COMPLETED

Sponsor

National Cancer Institute (NCI)

Enrollment

Started

1995

Neoplasm MetastasisOsteosarcoma

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

NCT00005822Phase 1COMPLETED

Sponsor

Case Comprehensive Cancer Center

Enrollment

Started

2000

Primary outcome

Determine the maximum tolerated dose of SU5416 and doxorubicin in patients with stage IIIB or IV inflammatory breast cancer.

Breast Cancer

Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer

NCT00424164Phase 1COMPLETED

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Enrollment

Started

2006

Primary outcome

Pharmacokinetic profile of lapatinib ditosylate and tamoxifen citrate alone and in combination

Breast Cancer

Tamoxifen in Patients With Oesophageal Cancer

NCT02513849Phase 1UNKNOWN

Sponsor

University of Nottingham

Enrollment

Started

2015

Primary outcome

A change in Ki67 expression following tamoxifen therapy, by comparing the pre- and post- tamoxifen biopsies

CancerGastrointestinal Neoplasms

Treatment Effect of Tamoxifen on Patients With DMD

NCT02835079Phase 1COMPLETED

Sponsor

Hadassah Medical Organization

Enrollment

Started

2016

Primary outcome

6-minute walk distance (6MWD)

Duchenne Muscular Dystrophy

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

NCT02586675Phase 1COMPLETED

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

Started

2016

Primary outcome

Recommended Phase II Dose (RP2D)

Breast CancerBreast Cancer - FemaleBreast Cancer - Male

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206Phase 1TERMINATED

Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

Started

2016

Primary outcome

Change in Ki67 Cell Percentage

Breast Cancer

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer

NCT00003080Phase 1COMPLETED

Sponsor

Fred Hutchinson Cancer Center

Started

1996

Ovarian Cancer

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

NCT02913430Early Phase 1COMPLETED

Sponsor

Shannon Puhalla

Enrollment

Started

2018

Primary outcome

Progression-free Survival (PFS)

Metastatic Breast Cancer

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

Download on theApp Store Get it onGoogle Play

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer